Neuromuscular abnormalities in critical illness;Les anomalies neuromusculaires acquises de réanimation

Revue Neurologique

Volumn 161, Issue 12, 2005, Pages 1267-1271

  Louillet, F ^a   Colas, F ^a   Outin, H D ^b   De Jonghe, B ^b   Sharshar, T ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL   (France)

Author keywords

Disability; IUC acquired neuromyopathy; Multiple organ failure; Steroids; Weaning risk factors

Indexed keywords

ARTIFICIAL VENTILATION; CLINICAL FEATURE; CRITICALLY ILL PATIENT; DIAPHRAGM PARALYSIS; DISEASE DURATION; FACE MUSCLE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIMB WEAKNESS; MULTIPLE ORGAN FAILURE; NEUROMUSCULAR DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; CRITICAL ILLNESS; INTENSIVE CARE; PERIPHERAL NEUROPATHY;

CRITICAL ILLNESS; HUMANS; INTENSIVE CARE; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 30944431907     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85239-7     Document Type: Review

References (50)

1. ADNET F, DHISSI G, BORRON SW et al. (2001). Complication profiles of adult asthmatics requiring paralysis during mechanical ventilation. Intensive Care Med, 27: 1729-1736.
2. BARRETT S, MOURANI S, VILLAREAL C, GONZALES J, ZIMMERMAN JE. (1993). Rhabdomyolysis associated with status asthmaticus. Crit Care Med, 21: 151-153.
3. BEDNARIK J, LUKAS Z, VONDRACEK P. (2003). Critical illness polyneuromyoathy: the electrophysiological components of a complex entity. Intensive Care Med, 29: 1505-1514.
4. BERCKER S, WEBER-CARSTENS S, DEJA M et al. (2005). Critical illness polyneuropathy and myopathy with acute respiratory distress syndrome. Crit Care Med, 33: 711-715.
5. BEREK K, MARGREITER J, WILLEIT J, BEREK A, SCHMUTZHARD E, MUTZ NJ. (1996). Polyneuropathies in critically ill patients: a prospective evaluation. Intensive Care Med, 22: 849-855.
6. BOLTON CF, GILBERT JJ, HAHN A F, SIBBALD WJ. (1984). Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry, 47: 1223-1231.
7. BOLTON CF. (1996). Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med, 24: 1408-1416.
8. BREASLEY D, BRAND M, HARGREAVES I et al. (2002). Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet, 360: 219-223.
9. BROOK AD, AHRENS TS, SCHAIFF R et al. (1999). Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med, 27: 2609-2615.
10. CAMPELLONE JV, LACOMIS D, KRAMER DJ, VAN COTT AC, GIULIANI MJ. (1998). Acute myopathy after liver transplantation Neurology, 50: 46-53.
11. COAKLEY JH. (1993). Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis. Intensive Care Med, 19: 323.
12. COAKLEY JH, NAGENDRAN K, YARWOOD GD, HONAVAR M, HINDS CJ. (1998). Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med, 24: 801-807.
13. COUTURIER J, ROBERT D, MONIER P. (1984). Polynévrites complicant des séjours prolongés en réanimation. Lyon Med, 252: 247-249.
14. DE JONGHE B, COOK D, SHARSHAR T, LEFAUCHEUR JP, CARLET J, OUTIN H. (1998). Acquired neuromuscular disorders in critically ill patients: a systematic review. Intensive Care Med, 24: 1242-1250.
15. DE JONGHE B, SHARSHAR T, LEFAUCHEUR JP et al. (2002). Paralysis acquired in the intensive care unit: a prospective multicenter cohort study. JAMA. 288: 862-871.
16. DE JONGHE B, BASTUJI-GARIN S, SHARSHAR T, OUTIN H, BROCHARD L. (2004a). Does ICU-acquired paresis lengthen weaning from mechanical ventilation. Intensive Care Med, 30: 1117-1121.
17. DE JONGHE B, SHARSHAR T, HOPKINSON N, OUTIN H. (2004b). Paresis following mechanical ventilation. Curr Opin Crit Care, 10: 47-52.
18. DE LETTER MA, VAN DOORN PA, SAVELKOUL HF et al. (2000a). Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol, 106: 206-213.
19. DE LETTER MA, VISSER LH, VAN DER MECHE FG, ANG W, SAVELKOUL HF. (2000b). Distinctions between critical illness polyneuropathy and axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry, 68: 397-398.
20. DE LETTER MA, SCHMITZ PI, VISSER LH et al. (2001). Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med, 29: 2281-2286.
21. DE SEZE M, PETIT H, WIART L et al. (2000). Critical illness polyneuropathy. A 2-year follow-up study in 19 severe cases. Eur Neurol, 43: 61-69.
22. DI GIOVANNI S, MOLON A, BROCCOLINI A et al. (2004). Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol, 55: 195-206.
23. DOUGLASS J A. (1992). Myopathy in severe asthma. Am Rev Respir Dis, 146: 517.
24. DU BOIS DC, ALMON RR. (1981). A possible role for glucocorticoids in denervation atrophy. Muscle Nerve, 4: 370-373.
25. FILATOV GN, RICH MM. (2004). Hyperpolarized shifts in the voltage dependence of fast inactivation of Nav 1.4 and Nav 1.5 in a rat model of critical illness myopathy. J Physiol, 559: 813-820.
26. FLETCHER SN, KENNEDY DD, GHOSH IR et al. (2003). Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med, 31: 1012-1016.
27. FRIEDRICH O, HUND E, WEBER C, HACKE W, FINK RH. (2004). Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol, 251: 53-65.
28. GARNACHO-MONTERO J, MADRAZO-OSUNA J, GARCIA-GARMENDIA JL et al. (2001). Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med, 27: 1288-1296.
29. GARNACHO-MONTERO J, AMAYA-VILLAR R, GARCIA-GARMENDIA JL, MADRAZO-OSUNA J, ORTIZ-LEYBA C. (2005). Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med, 33: 349-354.
30. GRIFFITHS RD, PALMER TE, HELLIWELL T, MACLENNAN P, MACMILLAN RR. (1995). Effect of passive stretching on the wasting of muscle in the critically ill. Nutrition, 11: 428-432.
31. HERRIDGE MS, CHEUNG AM, TANSEY CM et al. (2003). One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med, 348: 683-693.
32. HUDSON LD, LEE CM. (2003). Neuromuscular sequellae of critical illness. N Engl J Med, 348: 745-747.
33. HUND E. (2001). Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol, 248: 929-934.
34. KONAGAYA M, BERNARD PA, MAX SR. (1986). Blockade of glucocorticoid receptor binding and inhibition of dexamethasone-induced muscle atrophy in the rat by RU38486, a potent glucocorticoid antagonist. Endocrinology, 119: 375-380.
35. KRESS JP, POHLMAN AS, O'CONNOR MF, HALL JB. (2000). Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med, 342: 1471-1477.
36. LATRONICO N, FENZI F, RECUPERO D et al. (1996). Critical illness myopathy and neuropathy. Lancet, 347: 1579-1582.
37. LEATHERMAN JW, FLUEGEL WL, DAVID WS, DAVIES SF, IBER C. (1996). Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med, 153: 1686-1690.
38. MOHR M, ENGLISCH L, ROTH A, BURCHARDI H, ZIELMANN S. (1997). Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med, 23: 1144-1149.
39. RICH MM, PINTER MJ. (2003). Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol, 547: 555-566.
40. SANDER HW, GOLDEN M, DANON MJ. (2002). Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve, 26: 499-505.
41. SASSOON CS, CAIOZZO VJ, MANKA A, SIECK GC. (2002). Altered diaphragm contractile properties with controlled mechanical ventilation. J Appl Physiol, 92: 2585-2595.
42. SEGREDO V, CALDWELL J, MATTHAY M, SHARMA M, GRUENKE L, MILLER R. (1992). Persistant paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med, 327: 524-528.
43. TROJABORG W, WEIMER LH, HAYS AP. (2001). Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy - a reappraisal. Clin Neurophysiol, 112: 1586-1593.
44. VAN DEN BERGHE G, WOUTERS P, WEEKERS F et al. (2001). Intensive insulin therapy in the surgical intensive care unit. N Engl J Med, 345: 1359-1367.
45. VAN DEN BERGHE G, WOUTERS PJ, BOUILLON R et al. (2003). Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med, 31: 359-366.
46. VERHEUL GA, DE JONGH-LEUVENINK J, OP DE COUL AA, VAN LANDEGHEM AA, VAN PUYENBROEK MJ. (1994). Tumor necrosis factor and interleukin-6 in critical illness polyneuromyopathy. Clin Neurol Neurosurg, 96: 300-304.
47. WIJDICKS EF, FULGHAM JR. (1994). Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve, 17: 1494-1495.
48. WITT NJ, ZOCHODNE DW, BOLTON CF et al. (1991). Peripheral nerve function in sepsis and multiple organ failure. Chest, 99: 176-184.
49. ZIFKO UA, ZIPKO HT, BOLTON CF. (1998). Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci, 159: 186-193.
50. ZIFKO UA. (2000). Long-term outcome of critical illness polyneuropathy. Muscle Nerve, Suppl 9: S49-S52.